poisar

Stocks · News reference

Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO

BenzingaAug 4, 2026, 12:12 PMBenzinga Newsdesk

Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-IIPresenter: Hidetoshi Hayashi, Kindai University Faculty of

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 4, 2026, 12:12 PM
Checked
Aug 4, 2026, 12:12 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading